Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study.

A clinical trial, NCT06343038, is currently underway to test a new treatment for metastatic prostate cancer. The treatment involves using an antibody with a small amount of radioactive material. The study aims to compare the new treatment to the old one using low doses that do not cause adverse reactions. The trial also includes evaluating different diagnostic methods for prostate cancer. The trial is being conducted by the University Hospital in Basel, Switzerland, with an estimated completion date of June 2028. [Extracted from the article]

Copyright of Hematology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)